Cara Therapeutics Profit Margin

The latest profit margin for CARA is 1196.42% as of June 2026. That compares with -317.54% in the prior-year period — up 476.8% year over year. That is above the Healthcare sector average of 19.13%. Investors often review this figure alongside Cara Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CARA's profit margin moved from -317.54% to 1196.42% — a 476.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cara Therapeutics's valuation or profitability profile.

Against Healthcare companies, CARA currently prints 1196.42% for profit margin, while the sector average sits near 19.13%. That is roughly 6153.7% above the sector mean. Large gaps often invite a closer look at Cara Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Cara Therapeutics converts resources into returns. At 1196.42%, CARA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -317.54% in the prior-year period — up 476.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CARA's profit margin (1196.42%), review year-over-year change from -317.54%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.